Extended release bupivacaine hydrochloride resorbable matrix formulation

{
  "id": "MLC-T-ONC-013488",
  "term": "Extended release bupivacaine hydrochloride resorbable matrix formulation",
  "field": "Oncology and biomedicine",
  "definition": "An extended release (ER) injectable formulation composed of the hydrochloride salt form of bupivacaine, an amide-type, long-acting local anesthetic, in a resorbable sucrose acetate isobutyrate-based matrix, with analgesic activity. Following administration in or around a specific site, ER bupivacaine is released from the matrix over an extended period of time. Upon release, bupivacaine reversibly binds to specific voltage-gated sodium ion channels in the neuronal membrane, resulting in a decrease in the voltage-dependent membrane permeability to sodium ions, membrane destabilization, and depolarization inhibition thus disrupting nerve impulse conduction. This eventually leads to a reversible loss of sensation. This formulation may provide pain relief up to 72 hours.",
  "synonyms": [
    "SABER-bupivacaine chloride",
    "extended release bupivacaine hydrochloride",
    "ER bupivacaine HCl",
    "sustained release bupivacaine hydrochloride"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/extended-release-bupivacaine-hydrochloride-resorbable-matrix-formulation/"
}